Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IONIS-AGT-LRx · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| IONIS-AGT-LRx | EXPERIMENTAL | IONIS-AGT-LRX by subcutaneous injection once-weekly |
| Placebo | PLACEBO_COMPARATOR | Matching placebo by subcutaneous injection once-weekly |
| Pooled Placebo | PLACEBO_COMPARATOR | Participants received ISIS 757456 matching placebo subcutaneously once weekly for 12 weeks. |
| IONIS-AGT-LRx 80 mg | EXPERIMENTAL | Participants received ISIS 757456 80 milligrams (mg), subcutaneous (SC) injection, once weekly for 12 weeks. |
| IONIS-AGT-LRx 120 mg | EXPERIMENTAL | Participants received ISIS 757456 120 mg, SC injection, once weekly for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| IONIS-AGT-LRx | DRUG | Multiple doses of IONIS-AGT-LRx will be administered by SC injection. |
| Placebo | DRUG | IONIS-AGT-LRx-matching placebo will be administered by SC injection. |
Inclusion Criteria: 1. Females must be non-pregnant and non-lactating and of non- childbearing potential. 2. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), she must be willing to use a highly effective contraceptive...
IONIS-AGT-LRx is an investigational drug being studied for hypertension and chronic heart failure with reduced ejection fraction. It has been evaluated in clinical trials involving healthy volunteers, hypertensive participants with uncontrolled blood pressure, and participants with chronic heart failure with reduced ejection fraction. The drug is in Phase 2 development for these cardiovascular conditions.
IONIS-AGT-LRx targets angiotensinogen, a protein involved in blood pressure regulation. By reducing angiotensinogen levels, the drug aims to lower blood pressure. This mechanism is being investigated as a potential treatment for hypertension and chronic heart failure with reduced ejection fraction.
IONIS-AGT-LRx is developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety, tolerability, and efficacy in cardiovascular conditions.
IONIS-AGT-LRx is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials, including studies in healthy volunteers, hypertensive participants, and participants with chronic heart failure with reduced ejection fraction. The drug is investigational and not yet approved by regulatory authorities.
IONIS-AGT-LRx has been studied in three completed clinical trials. NCT03101878 was a Phase 1 study in healthy volunteers. NCT04714320 was a Phase 2 study in hypertensive participants with uncontrolled blood pressure. NCT04836182 was a Phase 2 study in participants with chronic heart failure with reduced ejection fraction.
Yes, IONIS-AGT-LRx is also referred to as Ionis AGT-LRx. The drug is developed by Ionis Pharmaceuticals and has been studied under both names in clinical trials. It targets angiotensinogen for the treatment of hypertension and chronic heart failure with reduced ejection fraction.